THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
Emmanouil Spanoudakis(Democritus University of Thrace), Ιoannis Kotsianidis(Democritus University of Thrace), Ioanna Bazntiara(Democritus University of Thrace), Xrisa Kordella(Democritus University of Thrace), Konstantinos Tilkeridis(Democritus University of Thrace), Eleftheria Lamprianidou(Democritus University of Thrace), Constantinos Tsatalas(Democritus University of Thrace), Menelaos Papoutselis(Democritus University of Thrace)
Cited by 9
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
|Journal of Clinical Oncology|2007|279
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160